Stockscreener 앱 받기
2.60
6.81%
-0.19
전일 마감가:
$2.79
열려 있는:
$2.82
하루 거래량:
3,216
Relative Volume:
0.37
시가총액:
$26.12M
수익:
-
순이익/손실:
$-42.19M
주가수익비율:
-4.127
EPS:
-0.63
순현금흐름:
$-25.32M
1주 성능:
-10.55%
1개월 성능:
+7.22%
6개월 성능:
-52.90%
1년 성능:
-60.00%
1일 변동 폭
$2.68
$2.8308
1주일 범위:
$2.66
$2.8308
52주 변동 폭
$2.16
$69.99
Sab Biotherapeutics Inc Stock (SABS) Company Profile
명칭
Sab Biotherapeutics Inc
전화
305-845-2813
주소
777 W 41ST ST, MIAMI BEACH
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-11-05 | 개시 | Chardan Capital Markets | Buy |
Sab Biotherapeutics Inc 주식(SABS)의 최신 뉴스
SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Update - Defense World
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference - GlobeNewswire
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference - StockTitan
SAB Biotherapeutics (NASDAQ:SABS) Given “Buy” Rating at Chardan Capital - Defense World
SAB BIO Provides SAB-142 Clinical Trial Progress Update at - GlobeNewswire
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the - The Bakersfield Californian
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting - StockTitan
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting - GlobeNewswire
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting - StockTitan
SAB Biotherapeutics (NASDAQ:SABS) Coverage Initiated by Analysts at Oppenheimer - Defense World
How To Buy SAB Biotherapeutics, Inc. Stock Online in August 2024 - Traders Union
Influenza Pipeline Drugs 2024 | Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG - Barchart
Chardan Capital Analysts Boost Earnings Estimates for SAB Biotherapeutics, Inc. (NASDAQ:SABS) - Defense World
SAB Biotherapeutics (NASDAQ:SABS) Receives Buy Rating from HC Wainwright - Defense World
SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Reaffirmed by Chardan Capital - Defense World
SABS stock touches 52-week low at $2.3 amid market challenges - Investing.com
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates - GlobeNewswire
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates - StockTitan
Seasonal Influenza Treatment Market Size 2032 | SAb - openPR
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes - GlobeNewswire
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes - StockTitan
SAB BIO Appoints Lucy To as Chief Financial Officer - citybiz
SAB BIO Appoints Lucy To as Chief Financial Officer - GlobeNewswire
SAB BIO Appoints Lucy To as Chief Financial Officer - StockTitan
SAB Biotherapeutics (NASDAQ:SABS) Trading Down 0.4% - American Banking and Market News
SAB Biotherapeutics (NASDAQ:SABS) Trading Down 0.4% - Defense World
MarketBeat June market recap - SiouxFalls.Business
SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021 - Quantisnow
Big Cypress Acquisition Corp. Reports Ladenburg Conference Presentation by Planned Merger Partner SAB Biotherapeutics - Quantisnow
SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS ... - Quantisnow
SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda ... - Quantisnow
SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human ... - Quantisnow
Reviewing SAB Biotherapeutics (NASDAQ:SABS) & Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) - Defense World
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Tenaya Therapeutics Announces Director Resignation By Investing.com - Investing.com
CSP Inc insider buys shares worth over $23,000 - Investing.com
Kintara Therapeutics restructures share designations By Investing.com - Investing.com
Broker Revenue Forecasts For SAB Biotherapeutics, Inc. (NASDAQ:SABS) Are Surging Higher - Yahoo New Zealand News
Need To Know: The Consensus Just Cut Its SAB Biotherapeutics, Inc. (NASDAQ:SABS) Estimates For 2022 - Yahoo Sport Australia
SAB Bio updates brand to reflect focus on type 1 diabetes therapy By Investing.com - Investing.com Australia
SAB Bio updates brand to reflect focus on type 1 diabetes therapy By Investing.com - Investing.com UK
SAB Biotherapeutics rebrands as SAB BIO; reaffirms full-year outlook (NASDAQ:SABS) - Seeking Alpha
SAb Biotherapeutics Rebrands as SAB BIO - GlobeNewswire
SAb Biotherapeutics Rebrands as SAB BIO | SABSW Stock News - StockTitan
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions - ForexTV.com
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions - GlobeNewswire
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions - Yahoo Finance
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions - StockTitan
BVF Inc. IL Acquires New Stake in SAB Biotherapeutics, Inc. (NASDAQ:SABS) - Defense World
FDA Greenlights First Drug in Nearly a Decade for Rare Liver Disease - BioSpace
Brookline Capital starts SAB Biotherapeutics stock with $8 PT, buy rating By Investing.com - Investing.com
Sab Biotherapeutics Inc (SABS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Sab Biotherapeutics Inc 주식 (SABS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| King Michael | CHIEF FINANCIAL OFFICER |
Nov 30 '23 |
Buy |
0.90 |
5,000 |
4,500 |
5,000 |
| Reich Samuel J | Executive Chairman |
Nov 29 '23 |
Buy |
0.89 |
11,000 |
9,842 |
219,001 |
1.26%
1.71%
자본화:
|
볼륨(24시간):